Human tissue analysis comparing prostaglandin levels in bald versus haired scalp from AGA patients, plus functional testing in explanted human hair follicles (ex vivo) and topical application in mice (in vivo).

Prostaglandin D2 synthase (PTGDS) and PGD2 itself are elevated in bald scalp. PGD2 directly inhibits hair growth in explanted human follicles and in mice through the GPR44 receptor. PGF2α and PGE2 -- the prostaglandins latanoprost mimics -- enhance hair growth in mice, creating a framework of pro-hair vs. anti-hair prostaglandins.

This is the foundational paper explaining why latanoprost might work on the scalp. The PGD2 elevation in bald scalp is robust human tissue data. The prostaglandin imbalance hypothesis is one of the strongest mechanistic frameworks in modern hair loss biology. However, it does not prove that adding PGF2α analogs corrects this imbalance therapeutically.

• Garza LA, Liu Y, Yang Z, et al. (2012). Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med PMID 22440736

Prospective studies of glaucoma patients receiving topical latanoprost 0.005% eye drops. Eyelash growth tracked as a documented side effect across multiple patient populations.

Glaucoma patients showed an average 19.5% increase in eyelash length with a mean treatment duration of 20 weeks. Both length and number increased. The mechanism: latanoprost induces anagen in resting telogen follicles, causes hypertrophic changes, and prolongs the anagen phase.

This is robust, replicated human data from thousands of patients that directly inspired the development of Latisse. But eyelash follicles have a very short natural anagen phase (~30 days vs. 2-6 years for scalp), making anagen prolongation far more visible. FP receptor expression patterns may differ between sites. Strong eyelash evidence does not automatically predict scalp efficacy.

• Johnstone MA, Albert DM (2002). Prostaglandin-induced hair growth. Surv Ophthalmol PMID 12204716

Randomized, double-blind, placebo-controlled pilot study. 16 men with mild AGA (Hamilton II-III) applied latanoprost 0.1% or placebo daily for 24 weeks on two minizones on the scalp. Hair density, diameter, pigmentation, and anagen/telogen ratio measured by phototrichography.

Hair density on the latanoprost-treated site increased significantly compared to baseline (P < 0.001) and placebo (P = 0.0004). Both vellus and terminal hair density increased at 24 weeks.

The p-values are impressive and the design is gold-standard. However: only 16 subjects (finasteride trials enrolled 1,500+), only mild AGA in young men, the 0.1% concentration is 20x higher than ophthalmic drops and caused 50% scalp irritation rates in some reports, the minizone design may not reflect whole-scalp efficacy, 24 weeks is short for AGA, and no replication in 14 years. A promising signal, not a definitive answer.

• Blume-Peytavi U, Lonnfors S, Engmeier H, et al. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol PMID 21875758

Primate study. 8 stump-tailed macaques divided into two groups: daily topical latanoprost 50 µg/mL for 5 months vs. vehicle. Then 2 monkeys from each group escalated to 500 µg/mL for 3 additional months. Hair growth assessed by photographs and phototrichographic analysis.

50 µg/mL caused minimal hair growth. 500 µg/mL induced moderate to marked regrowth with 5-10% conversion of vellus hairs to intermediary or terminal hairs.

Stump-tailed macaques are the gold-standard AGA animal model. The dose-response relationship and vellus-to-terminal conversion are biologically meaningful. But only 8 monkeys, the effective dose is substantially higher than typical human formulations, and the 5-10% conversion rate is modest. Primate results are more relevant than mouse data but still don't guarantee human scalp translation.

• Uno H, Zimbric ML, Albert DM, Stjernschantz J (2002). Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol PMID 12013211

Human hair follicle organ culture. Matched female pre-auricular facelift skin hair follicles (both terminal and intermediate/miniaturized) incubated with PGF2α (100 nM) alone or with an FP receptor antagonist for 9 days.

PGF2α stimulated terminal follicle growth by 4.93% and intermediate follicle growth by 10.03%. Anagen duration was significantly prolonged in both types. Growth effects were completely blocked by the FP antagonist. FP receptor was confirmed in dermal papilla and connective tissue sheath by immunohistochemistry.

Direct evidence that PGF2α stimulates human hair growth through confirmed receptor biology. The stronger response in miniaturized follicles is particularly relevant for AGA, where the therapeutic goal is rescuing miniaturizing follicles. FP receptor localization in dermal papilla provides a clear cellular target. However, ex vivo conditions lack the full in vivo environment, effect sizes are modest, and this tests PGF2α itself rather than latanoprost.

• Guiha I, Bertolini M, Paus R, et al. (2025). Prostaglandin F2α stimulates the growth of human intermediate hair follicles in ex vivo organ culture with potential clinical relevance. Front Physiol PMID 40606226

Multiple large randomized controlled trials of bimatoprost 0.03% applied to upper eyelid margins for eyelash hypotrichosis. Pivotal trial: 16 weeks, multicenter, double-masked, vehicle-controlled.

Bimatoprost increased eyelash length by 25% at 16 weeks. 78% of users achieved at least one-grade improvement in eyelash prominence. Treated follicles showed significantly greater anagen proportion and decreased telogen proportion. FDA approved in 2008.

The FDA approval of Latisse proves prostaglandin analogs can grow hair via FP/prostamide receptor agonism. However, Allergan ran Phase 2 scalp AGA efficacy trials (NCT01325337, n=307, which included a minoxidil 5% active comparator, and NCT01904721, n=244; results posted on ClinicalTrials.gov). Bimatoprost solutions modestly beat vehicle on hair count but did not match minoxidil 5% (NCT01325337: best bimatoprost +13.1 vs minoxidil +21.9 vs vehicle +4.1 hairs/cm2), so the scalp program was discontinued for non-superiority to minoxidil, not for lack of efficacy.

• Smith S, Fagien S, Whitcup SM, et al. (2012). Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol
• FDA (2008). Latisse (bimatoprost ophthalmic solution 0.03%) NDA 022369 approval

Systematic review and meta-analysis of 6 randomized controlled trials from PubMed, Embase, and Cochrane Library comparing topical prostaglandin analogs (bimatoprost, latanoprost, cetirizine) with placebo for various forms of hair loss.

Prostaglandin analogs significantly improved hair length and density compared to placebo (P < 0.001). No significant difference in adverse event rates between treatment and control groups.

The overall signal is positive: as a class, prostaglandin analogs appear to promote hair growth with acceptable safety. However, the pooling of different drugs, different alopecia types, and different outcome measures limits how much you can infer about latanoprost for AGA specifically. Including cetirizine (a different mechanism) further muddies the prostaglandin-specific conclusions.

• Jiang T, Xie Y, Zhu Y, et al. (2023). The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis. Front Med PMID 36999072

Multiple designs: RCT of latanoprost 0.005% for scalp alopecia areata (Rafati 2022); prospective study for eyelash alopecia areata universalis; 2024 case report of latanoprost 0.005% twice daily for frontal fibrosing alopecia.

In scalp alopecia areata, latanoprost 0.005% increased hair density and regrowth but was less effective than betamethasone dipropionate 0.05%. For eyelash alopecia areata universalis, 45% achieved moderate-to-complete regrowth. In FFA, a single patient showed disease stabilization at 10 months with no adverse effects.

These findings suggest latanoprost's effects extend beyond AGA, involving mechanisms beyond just prostaglandin pathway modulation (anti-inflammatory properties). However, the alopecia areata RCT showed inferiority to standard therapy, and the FFA evidence is a single case. Relevant for consumers because it suggests multi-mechanism activity that could make latanoprost useful as an adjunct.

• Rafati A, Hooshmand F, Kalantari S, et al. (2022). The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial. Dermatol Ther PMID 35289043
• Coronel-Perez IM, Ruiz-Villaverde R (2010). Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol PMID 20028444
• JAAD Case Reports (2024). Stabilization of frontal fibrosing alopecia with topical latanoprost monotherapy. JAAD Case Rep